Hub : Traits :

HDL Cholesterol

681 significantly associated models · 171 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	26327671	27882335	3	1	9.3e-09	2.8e-07	3.6e-01	97	ZDHHC18
2	1	39182130	40737589	5	1	5.5e-11	4.0e-10	1.0e+00	100	PABPC4
3	1	93377792	93883331	1	1	1.7e-07	4.1e-07	2.8e-01	95	TMED5
4	1	109098737	110517617	3	1	4.9e-08	6.2e-08	4.1e-01	98	SORT1
5	1	229499636	231115887	1	1	7.9e-21	3.7e-21	1.0e+00	100	GALNT2
6	2	20062043	21544066	1	1	5.8e-08	1.2e-30	3.1e-30	1	HS1BP3
7	2	84849386	86275985	3	1	8.9e-08	1.0e-07	1.4e-01	92	RETSAT
8	2	164657815	166170073	1	1	6.9e-10	2.7e-10	1.0e+00	100	GRB14
9	3	49030828	50448632	1	1	2.9e-07	1.4e-06	5.1e-01	98	RNF123
10	3	52322680	52821177	1	1	1.9e-07	5.6e-07	6.9e-02	87	LOC440957
11	4	87165758	88754060	1	1	4.7e-08	1.2e-06	1.1e-01	89	AFF1
12	6	33856903	35549670	3	1	3.7e-10	3.8e-09	8.3e-01	100	C6orf106
13	7	6170312	6690270	1	1	1.6e-07	1.4e-06	9.8e-01	100	RAC1
14	7	72674074	73738067	2	5	1.1e-09	1.2e-09	1.0e+00	100	BCL7B MLXIPL
15	7	129917130	131315092	1	1	1.7e-08	1.2e-15	1.1e-08	49	RP11-138A9.1
16	8	19064892	20858217	2	4	1.7e-99	9.7e-98	1.9e-01	100	LPL LZTS1
17	9	14472090	15994724	1	1	7.8e-15	1.3e-13	3.9e-01	99	TTC39B
18	9	106846396	108380721	1	1	8.1e-18	1.7e-33	1.8e-17	50	ABCA1
19	11	46010847	48783497	24	2	1.0e-20	1.5e-16	2.2e-01	98	ACP2 NUP160
20	11	60549966	62346131	7	2	7.1e-23	2.2e-22	1.0e+00	100	C11orf10 FEN1
21	11	115953897	117767498	6	6	5.3e-43	1.2e-28	1.0e+00	100	AP006216.12 APOA1 BUD13 ZNF259
22	12	19826892	21533355	1	1	3.4e-08	3.8e-08	1.0e+00	100	PDE3A
23	12	108763672	110729807	7	1	1.8e-15	6.9e-15	2.2e-01	98	KCTD10
24	12	123040985	125270773	9	2	7.7e-16	2.6e-14	3.1e-12	16	CDK2AP1 RP11-380L11.3
25	15	58004888	59737506	2	3	6.1e-42	2.9e-96	1.9e-45	54	ADAM10 LIPC
26	15	62636766	64056437	4	1	1.8e-08	1.9e-08	1.0e+00	100	RP11-244F12.2
27	16	55789570	58178596	10	9	0.0e+00	2.1e-306	NaN	NaN	CETP MT1L NLRC5 OGFOD1 SLC12A3
28	16	66542957	69084178	33	8	7.2e-35	8.4e-33	1.0e+00	100	B3GNT9 DUS2 FHOD1 GFOD2 LCAT NRN1L PRMT7
29	17	36710513	39048774	15	1	1.5e-15	8.7e-14	1.3e-01	96	PGAP3
30	19	8182620	8848856	3	2	4.0e-08	4.0e-08	1.0e+00	100	ANGPTL4 MYO1F
31	19	45162038	45695738	3	1	2.3e-10	4.4e-21	1.9e-18	14	APOC1
32	19	52049899	52574723	1	1	1.5e-07	1.7e-07	1.0e+00	100	FPR3
33	19	54106547	55427510	2	1	1.4e-17	1.4e-15	4.2e-01	99	LILRA3
34	20	43766067	45235570	7	4	8.3e-16	1.9e-22	2.2e-05	81	CTSA MMP9 PLTP ZSWIM1
35	22	21075537	22685340	4	1	3.8e-10	1.1e-08	9.8e-01	100	CCDC116

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Triglycerides	43.21	23	17	37.8	-0.74	3.2e-06	ACP2 AFF1 BCL7B BUD13 C11orf10 CETP CTSA FEN1 GALNT2 GRB14 HS1BP3 LIPC LOC440957 LPL LZTS1 MLXIPL MMP9 NLRC5 PABPC4 PLTP RP11-380L11.3 ZNF259 ZSWIM1
LDL Cholesterol	12.49	12	9	20.0	-0.58	3.1e-02	ABCA1 APOC1 BUD13 C11orf10 C6orf106 CETP FEN1 HS1BP3 NLRC5 SORT1 ZDHHC18 ZNF259
High cholesterol (Self-reported)	10.18	11	6	13.3	-0.61	1.2e-02	ABCA1 APOC1 BCL7B BUD13 FEN1 HS1BP3 LPL MLXIPL SORT1 ZDHHC18 ZNF259
Cholesterol lowering medication	7.37	8	6	13.3	-0.40	2.5e-01	ABCA1 BUD13 LPL RP11-138A9.1 RP11-380L11.3 SORT1 ZDHHC18 ZNF259
Medication: Cholesterol lowering	7.04	5	4	8.9	-0.75	2.1e-02	BUD13 CETP LPL SORT1 ZNF259
Medication: Simvastatin	5.94	9	3	6.7	-0.76	3.9e-03	BUD13 C11orf10 CETP FEN1 LPL NLRC5 SORT1 ZDHHC18 ZNF259
Waist Hip Ratio (WHR)	5.91	14	9	20.0	-0.30	2.3e-01	ABCA1 BCL7B BUD13 C6orf106 CDK2AP1 DUS2 GRB14 LOC440957 LPL MLXIPL MYO1F PDE3A RP11-138A9.1 RP11-380L11.3
Medication: Atorvastatin	5.76	5	3	6.7	-0.01	9.8e-01	ABCA1 BUD13 LPL SORT1 ZNF259
Medication for cholesterol, blood pressure or diabetes	3.96	6	3	6.7	0.83	9.9e-03	BUD13 CETP LPL MLXIPL SORT1 ZNF259
Cardiovascular Disease	3.24	13	6	13.3	-0.79	1.1e-04	ACP2 BCL7B BUD13 CTSA LPL MLXIPL MYO1F PABPC4 RP11-138A9.1 RP11-244F12.2 SORT1 ZDHHC18 ZNF259
Blood White Count	3.22	18	11	24.4	-0.45	4.1e-02	AFF1 APOC1 BCL7B C11orf10 C6orf106 CCDC116 CDK2AP1 CTSA FEN1 LOC440957 MLXIPL NLRC5 NUP160 PGAP3 RETSAT RNF123 RP11-138A9.1 RP11-380L11.3
Gout (self-reported)	3.03	1	1	2.2	-0.79	2.1e-01	MLXIPL
Hip circumference	3.01	10	7	15.6	0.18	5.5e-01	ABCA1 ACP2 BCL7B C6orf106 GRB14 MLXIPL PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Blood Platelet Count	2.82	19	15	33.3	0.04	8.6e-01	ACP2 APOA1 APOC1 BCL7B BUD13 C11orf10 C6orf106 DUS2 FEN1 GALNT2 MLXIPL PABPC4 PGAP3 PLTP RETSAT RP11-244F12.2 TMED5 ZDHHC18 ZNF259
Coronary Artery Disease (CAD)	2.75	3	1	2.2	0.00	1.0e+00	BUD13 LPL RP11-380L11.3
Pulse rate, automated reading	2.66	8	6	13.3	-0.76	1.8e-02	C11orf10 C6orf106 FEN1 LOC440957 MLXIPL PABPC4 PDE3A PGAP3
Medication for cholesterol	2.64	2	2	4.4	0.00	1.0e+00	RP11-138A9.1 SORT1
Respiratory disease	2.61	5	2	4.4	-0.24	6.9e-01	C11orf10 FEN1 PABPC4 PGAP3 RNF123
Arm predicted mass (right)	2.59	10	5	11.1	0.01	9.7e-01	BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 PABPC4 RAC1 RNF123 SORT1
Arm fat-free mass (right)	2.57	9	5	11.1	0.11	7.4e-01	BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 RAC1 RNF123 SORT1
Blood Red Count	2.54	23	17	37.8	0.16	4.6e-01	AFF1 APOA1 C11orf10 C6orf106 CTSA FEN1 FHOD1 GFOD2 GRB14 HS1BP3 LCAT LILRA3 LOC440957 MMP9 NRN1L PABPC4 PGAP3 PRMT7 RP11-138A9.1 RP11-244F12.2 RP11-380L11.3 TMED5 ZSWIM1
Trunk predicted mass	2.49	13	5	11.1	0.05	8.4e-01	ACP2 BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 OGFOD1 PABPC4 RAC1 RNF123 RP11-380L11.3 SORT1
Number of treatments/medications taken	2.48	4	1	2.2	-0.26	7.4e-01	C11orf10 FEN1 RNF123 SORT1
Trunk fat-free mass	2.48	12	5	11.1	0.12	6.8e-01	ACP2 BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 OGFOD1 PABPC4 RAC1 RNF123 SORT1
Arm predicted mass (left)	2.46	10	4	8.9	-0.02	9.5e-01	BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 PABPC4 RAC1 RNF123 SORT1
Medication: Aspirin	2.41	2	1	2.2	0.00	1.0e+00	LPL SORT1
Medication: Aspirin	2.39	2	1	2.2	0.00	1.0e+00	LPL SORT1
Arm fat-free mass (left)	2.39	9	4	8.9	0.06	8.6e-01	BCL7B C6orf106 LOC440957 MLXIPL MYO1F NUP160 RAC1 RNF123 SORT1
Trunk fat percentage	2.38	9	6	13.3	-0.10	8.0e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Impedance of arm (right)	2.36	8	5	11.1	0.01	9.9e-01	BCL7B C6orf106 GRB14 LOC440957 MLXIPL RAC1 RNF123 RP11-380L11.3
Whole body fat-free mass	2.35	12	5	11.1	0.04	8.9e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F NUP160 OGFOD1 PABPC4 RAC1 RNF123 SORT1
Whole body water mass	2.35	12	5	11.1	0.04	8.9e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F NUP160 OGFOD1 PABPC4 RAC1 RNF123 SORT1
Medication: Allopurinol	2.34	2	1	2.2	-1.00	2.2e-04	MLXIPL ZDHHC18
Basal metabolic rate	2.30	10	5	11.1	-0.13	6.8e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F OGFOD1 PABPC4 RNF123 SORT1
Impedance of arm (left)	2.29	6	6	13.3	0.36	3.5e-01	GRB14 LOC440957 MLXIPL RAC1 RNF123 RP11-380L11.3
Illnesses of father: Heart disease	2.29	2	1	2.2	0.00	1.0e+00	LPL SORT1
Trunk fat mass	2.28	7	5	11.1	-0.02	9.7e-01	C6orf106 DUS2 GRB14 PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Weight	2.26	8	6	13.3	-0.12	7.4e-01	C6orf106 GRB14 KCTD10 MLXIPL MYO1F PABPC4 RNF123 RP11-380L11.3
Heart attack/myocardial infarction (self-reported)	2.26	2	1	2.2	0.00	1.0e+00	LPL SORT1
Heart attack	2.25	2	1	2.2	0.00	1.0e+00	LPL SORT1
Asthma (self-reported)	2.24	2	2	4.4	0.00	1.0e+00	FEN1 PGAP3
Body fat percentage	2.22	8	6	13.3	-0.01	9.8e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 RNF123 RP11-138A9.1 RP11-380L11.3
Leg fat-free mass (left)	2.17	9	5	11.1	-0.16	6.2e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F OGFOD1 PABPC4 RNF123
Whole body fat mass	2.17	7	4	8.9	-0.23	6.2e-01	C6orf106 GALNT2 GRB14 PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Leg predicted mass (left)	2.16	9	5	11.1	-0.16	6.3e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F OGFOD1 PABPC4 RNF123
Leg fat-free mass (right)	2.16	9	5	11.1	-0.14	6.8e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F OGFOD1 PABPC4 RNF123
Leg predicted mass (right)	2.16	9	5	11.1	-0.14	6.8e-01	BCL7B C6orf106 KCTD10 LOC440957 MLXIPL MYO1F OGFOD1 PABPC4 RNF123
Arm fat percentage (left)	2.15	9	6	13.3	-0.18	6.4e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Fasting Glucose	2.14	1	1	2.2	0.00	1.0e+00	FEN1
Asthma	2.13	2	2	4.4	0.00	1.0e+00	FEN1 PGAP3
Angina (self-reported)	2.11	2	2	4.4	0.00	1.0e+00	LPL SORT1
Average weekly champagne plus white wine intake	2.11	2	1	2.2	0.00	1.0e+00	C11orf10 FEN1
Leg fat mass (left)	2.10	5	4	8.9	0.24	7.0e-01	C6orf106 GRB14 NUP160 RNF123 RP11-380L11.3
Leg fat mass (right)	2.08	4	4	8.9	0.22	7.8e-01	C6orf106 GRB14 RNF123 RP11-380L11.3
Angina	2.06	2	1	2.2	0.00	1.0e+00	LPL SORT1
Arm fat percentage (right)	2.06	9	6	13.3	-0.18	6.5e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Blood Eosinophil Count	2.05	20	13	28.9	0.46	2.3e-02	B3GNT9 BUD13 C11orf10 CCDC116 CDK2AP1 DUS2 FEN1 FPR3 LCAT LPL MLXIPL MYO1F NLRC5 PGAP3 RNF123 RP11-138A9.1 TMED5 TTC39B ZDHHC18 ZNF259
Arm fat mass (left)	2.05	7	5	11.1	-0.31	5.0e-01	C6orf106 GALNT2 GRB14 NUP160 PABPC4 RNF123 RP11-380L11.3
Type 2 Diabetes (T2D) (2018)	2.03	5	2	4.4	-0.69	2.0e-01	GRB14 LPL PABPC4 RP11-138A9.1 RP11-380L11.3
Arm fat mass (right)	2.01	7	5	11.1	-0.31	4.9e-01	C6orf106 GALNT2 GRB14 NUP160 PABPC4 RNF123 RP11-380L11.3
Crohns Disease (2017)	1.98	3	2	4.4	0.00	1.0e+00	CCDC116 FEN1 PGAP3
Crohns Disease (2012)	1.98	3	0	0.0	0.00	1.0e+00	CCDC116 FEN1 PGAP3
Medication: Blood pressure	1.98	2	1	2.2	0.00	1.0e+00	ACP2 RP11-138A9.1
Hypothyroidism (self reported)	1.94	5	3	6.7	0.61	2.8e-01	AFF1 AP006216.12 C11orf10 FEN1 LCAT
Lung FEV1/FVC ratio	1.92	11	7	15.6	0.33	3.0e-01	B3GNT9 C6orf106 CTSA GFOD2 LCAT MYO1F NRN1L PABPC4 PDE3A PRMT7 SORT1
Pulse rate	1.92	2	1	2.2	0.00	1.0e+00	C11orf10 FEN1
Impedance of whole body	1.89	9	4	8.9	0.45	1.4e-01	C6orf106 DUS2 GRB14 LCAT LOC440957 MLXIPL OGFOD1 RNF123 RP11-380L11.3
BMI	1.85	13	9	20.0	-0.20	4.8e-01	ACP2 C6orf106 GALNT2 GRB14 KCTD10 LOC440957 MLXIPL NUP160 OGFOD1 PABPC4 RAC1 RNF123 RP11-380L11.3
Schizophrenia vs Biploar Disorder	1.84	1	0	0.0	0.00	1.0e+00	RNF123
Type 2 Diabetes (T2D) (2012)	1.82	1	0	0.0	0.00	1.0e+00	RP11-138A9.1
Leg fat percentage (left)	1.82	8	5	11.1	-0.15	7.2e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 RNF123 RP11-138A9.1 RP11-380L11.3
Fluid intelligence score	1.81	2	1	2.2	0.00	1.0e+00	NUP160 RNF123
Leg fat percentage (right)	1.81	8	4	8.9	-0.10	8.1e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 RNF123 RP11-138A9.1 RP11-380L11.3
Sitting height	1.78	12	5	11.1	0.26	3.5e-01	ACP2 B3GNT9 BCL7B C11orf10 C6orf106 CCDC116 FEN1 MLXIPL MYO1F NUP160 PABPC4 SLC12A3
Wheeze or whistling in the chest in last year	1.78	3	1	2.2	0.00	1.0e+00	FEN1 PGAP3 RNF123
Lupus	1.77	1	1	2.2	0.00	1.0e+00	CCDC116
Hearing difficulty/problems: Yes	1.75	1	0	0.0	0.00	1.0e+00	KCTD10
Intelligence (Savage-Jansen 2018)	1.73	5	2	4.4	-0.45	3.7e-01	FEN1 LCAT NRN1L NUP160 RNF123
Standing height	1.72	12	9	20.0	0.31	3.0e-01	ACP2 BCL7B C11orf10 C6orf106 CCDC116 DUS2 FEN1 MLXIPL MYO1F NUP160 SORT1 ZDHHC18
Father's age at death	1.70	2	0	0.0	0.00	1.0e+00	LPL SORT1
Irritable Bowel Disease (IBD)	1.69	2	2	4.4	0.00	1.0e+00	CCDC116 PGAP3
Body mass index (BMI)	1.69	9	4	8.9	-0.49	1.8e-01	ACP2 C6orf106 GALNT2 GRB14 NUP160 OGFOD1 PABPC4 RNF123 RP11-380L11.3
Birth weight	1.68	3	1	2.2	0.00	1.0e+00	BCL7B FHOD1 MLXIPL
Height	1.67	21	15	33.3	0.26	2.1e-01	ACP2 APOC1 BCL7B C11orf10 C6orf106 CCDC116 CTSA DUS2 FEN1 GALNT2 LPL MLXIPL MYO1F NUP160 PABPC4 SLC12A3 SORT1 TMED5 ZDHHC18 ZNF259 ZSWIM1
Verbal and Numeric Reasoning (VNR)	1.66	5	0	0.0	0.28	6.4e-01	C11orf10 FEN1 LOC440957 NUP160 RNF123
Hypothyroidism/myxoedema (self-reported)	1.66	3	0	0.0	0.00	1.0e+00	C11orf10 FEN1 LCAT
Medication: Blood pressure	1.66	1	0	0.0	0.00	1.0e+00	ACP2
Frequency of tiredness / lethargy in last 2 weeks	1.65	2	1	2.2	0.00	1.0e+00	KCTD10 PABPC4
Alcohol intake versus 10 years previously	1.64	1	0	0.0	0.00	1.0e+00	PABPC4
Primary Biliary Cirrhosis	1.63	1	0	0.0	0.00	1.0e+00	PGAP3
Alcohol intake frequency.	1.60	3	1	2.2	-0.97	1.1e-03	MLXIPL PGAP3 RNF123
Allergy	1.59	4	1	2.2	0.29	7.1e-01	C6orf106 CCDC116 FEN1 PGAP3
Mouth/teeth dental problems: Bleeding gums	1.57	1	0	0.0	0.00	1.0e+00	KCTD10
Taking other prescription medications	1.56	1	0	0.0	0.00	1.0e+00	RNF123
Ever highly irritable/argumentative for 2 days	1.56	1	0	0.0	0.00	1.0e+00	RNF123
Medication: Ventolin 100micrograms inhaler	1.55	1	1	2.2	0.00	1.0e+00	PGAP3
Medication: Levothyroxine sodium	1.53	2	1	2.2	0.00	1.0e+00	C11orf10 FEN1
Impedance of leg (left)	1.51	10	5	11.1	0.25	4.1e-01	C6orf106 CCDC116 DUS2 KCTD10 LCAT LOC440957 MLXIPL OGFOD1 PABPC4 RNF123
Medication for pain relief, constipation, heartburn	1.51	1	0	0.0	0.00	1.0e+00	C6orf106
Comparative height size at age 10	1.51	8	6	13.3	0.28	5.0e-01	ACP2 C6orf106 CCDC116 DUS2 MYO1F NUP160 SORT1 TMED5
Diabetes diagnosed by doctor	1.51	4	0	0.0	-0.98	1.8e-02	PABPC4 RNF123 RP11-138A9.1 RP11-380L11.3
Impedance of leg (right)	1.50	8	5	11.1	0.39	2.3e-01	C6orf106 CCDC116 DUS2 LOC440957 MLXIPL OGFOD1 PABPC4 RNF123
Suffer from 'nerves'	1.50	1	1	2.2	0.00	1.0e+00	NUP160
Birth weight of first child	1.49	2	0	0.0	0.00	1.0e+00	FHOD1 RAC1
Qualifications: College or University degree	1.49	2	2	4.4	0.00	1.0e+00	RNF123 TMED5
Knee pain experienced in last month	1.49	2	0	0.0	0.00	1.0e+00	PABPC4 RNF123
Myopia	1.49	1	0	0.0	0.00	1.0e+00	FEN1
Loneliness, isolation	1.48	1	1	2.2	0.00	1.0e+00	NUP160
Heel T-Score	1.46	16	8	17.8	-0.27	3.2e-01	ACP2 AFF1 B3GNT9 C11orf10 CCDC116 CTSA DUS2 FEN1 FPR3 MMP9 PABPC4 RNF123 RP11-244F12.2 RP11-380L11.3 SORT1 ZSWIM1
Irritability	1.46	3	0	0.0	0.00	1.0e+00	ANGPTL4 FEN1 KCTD10
Waist circumference	1.45	4	3	6.7	-0.99	9.9e-03	C6orf106 MYO1F PABPC4 RNF123
Qualifications: A levels/AS levels or equivalent	1.45	3	1	2.2	0.00	1.0e+00	CTSA RNF123 TMED5
Medication: Metformin	1.44	2	0	0.0	0.00	1.0e+00	LPL RP11-138A9.1
Diabetes (self-reported)	1.44	3	0	0.0	0.00	1.0e+00	PABPC4 RNF123 RP11-380L11.3
Age at First Birth	1.43	1	0	0.0	0.00	1.0e+00	RNF123
Heel bone mineral density (BMD) T-score, automated (left)	1.43	3	1	2.2	0.00	1.0e+00	ACP2 FEN1 RP11-380L11.3
Heel bone mineral density (BMD) T-score, automated (right)	1.43	4	2	4.4	0.18	8.2e-01	ACP2 B3GNT9 FEN1 RP11-380L11.3
Pain experienced in last month	1.42	2	1	2.2	0.00	1.0e+00	KCTD10 PABPC4
Supplements: Fish oil (including cod liver oil)	1.41	1	0	0.0	0.00	1.0e+00	FEN1
Bipolar Disorder or Schizophrenia	1.40	3	0	0.0	0.00	1.0e+00	LCAT PGAP3 PRMT7
Depression (Nagel 2018)	1.39	1	0	0.0	0.00	1.0e+00	NUP160
Long-standing illness, disability or infirmity	1.39	1	0	0.0	0.00	1.0e+00	CCDC116
Mood swings	1.38	1	0	0.0	0.00	1.0e+00	NUP160
Miserableness	1.38	2	0	0.0	0.00	1.0e+00	KCTD10 NUP160
Forced expiratory volume in 1-second (FEV1), predicted	1.37	3	1	2.2	0.00	1.0e+00	ACP2 C6orf106 MYO1F
Alzheimer’s Disease (including proxy)	1.36	1	0	0.0	0.00	1.0e+00	LILRA3
Medication: Omeprazole	1.36	1	0	0.0	0.00	1.0e+00	C6orf106
Worry (Nagel 2018)	1.35	3	1	2.2	0.00	1.0e+00	KCTD10 LOC440957 NUP160
Allergy or Eczema	1.35	4	2	4.4	-0.55	4.5e-01	C6orf106 CCDC116 PGAP3 TMED5
Neuroticism	1.35	2	2	4.4	0.00	1.0e+00	KCTD10 NUP160
Vascular/heart problems diagnosed by doctor	1.35	2	1	2.2	0.00	1.0e+00	ACP2 RP11-138A9.1
Frequency of tenseness / restlessness in last 2 weeks	1.34	1	0	0.0	0.00	1.0e+00	KCTD10
Overall health rating	1.34	2	0	0.0	0.00	1.0e+00	C6orf106 RNF123
Depressed Affect (Nagel 2018)	1.33	2	1	2.2	0.00	1.0e+00	KCTD10 NUP160
Schizophrenia (2014)	1.33	2	0	0.0	0.00	1.0e+00	LCAT PRMT7
Neuroticism score	1.33	2	2	4.4	0.00	1.0e+00	KCTD10 NUP160
Number of live births	1.33	1	0	0.0	0.00	1.0e+00	FEN1
Mouth/teeth dental problems: Dentures	1.33	3	0	0.0	0.00	1.0e+00	PGAP3 RNF123 TMED5
Hypertension (Self-reported)	1.33	2	1	2.2	0.00	1.0e+00	ACP2 RP11-138A9.1
Illnesses of siblings: Diabetes	1.33	1	0	0.0	0.00	1.0e+00	RP11-380L11.3
High blood pressure	1.32	3	1	2.2	0.00	1.0e+00	ACP2 RP11-138A9.1 ZDHHC18
Forced vital capacity (FVC), Best measure	1.32	5	2	4.4	0.26	6.7e-01	ACP2 C6orf106 CTSA MYO1F NUP160
Neck or shoulder pain in last month	1.32	1	0	0.0	0.00	1.0e+00	PABPC4
Bipolar Disorder (2018)	1.28	2	0	0.0	0.00	1.0e+00	C11orf10 FEN1
Neuroticism (Nagel 2018)	1.28	2	2	4.4	0.00	1.0e+00	KCTD10 NUP160
Schizophrenia (2018)	1.28	2	0	0.0	0.00	1.0e+00	LCAT PRMT7
Hayfever, allergic rhinitis or eczema	1.27	4	1	2.2	-0.61	3.9e-01	C6orf106 CCDC116 PGAP3 TMED5
Hand grip strength (right)	1.26	2	0	0.0	0.00	1.0e+00	C6orf106 MYO1F
Headache pain in last month	1.25	1	0	0.0	0.00	1.0e+00	AFF1
Age at first live birth	1.25	1	1	2.2	0.00	1.0e+00	RNF123
Smoking status: Current	1.25	1	0	0.0	0.00	1.0e+00	NUP160
Current tobacco smoking	1.24	1	0	0.0	0.00	1.0e+00	NUP160
Medication: Paracetamol	1.24	1	0	0.0	0.00	1.0e+00	TMED5
Ulcerative Colitis (UC)	1.23	1	1	2.2	0.00	1.0e+00	PGAP3
Age when periods started (menarche)	1.23	2	1	2.2	0.00	1.0e+00	LOC440957 NUP160
Medication: Omeprazole (e.g. Zanprol)	1.21	1	0	0.0	0.00	1.0e+00	C6orf106
Ulcerative Colitis	1.20	1	1	2.2	0.00	1.0e+00	PGAP3
Forced vital capacity (FVC)	1.19	5	3	6.7	-0.26	6.7e-01	ACP2 C6orf106 MYO1F NRN1L NUP160
Frequency of depressed mood in last 2 weeks	1.17	1	0	0.0	0.00	1.0e+00	NUP160
Falls in the last year	1.17	1	0	0.0	0.00	1.0e+00	KCTD10
Systolic Blood Pressure	1.16	9	3	6.7	-0.72	2.9e-02	ACP2 CCDC116 FHOD1 GRB14 RAC1 RP11-138A9.1 RP11-244F12.2 RP11-380L11.3 ZDHHC18
Back pain experienced in last month	1.16	1	0	0.0	0.00	1.0e+00	C6orf106
Seen a psychiatrist for nerves, anxiety, tension or depression	1.15	1	0	0.0	0.00	1.0e+00	FEN1
Mouth/teeth dental problems	1.14	1	0	0.0	0.00	1.0e+00	KCTD10
Smoking Status	1.13	3	1	2.2	0.00	1.0e+00	C6orf106 NUP160 PGAP3
Diastolic blood pressure, automated reading	1.12	2	0	0.0	0.00	1.0e+00	MLXIPL PDE3A
Relative age of first facial hair	1.11	2	0	0.0	0.00	1.0e+00	C6orf106 ZDHHC18
Sensitivity / hurt feelings	1.09	1	1	2.2	0.00	1.0e+00	KCTD10
Reaction Time	1.07	1	0	0.0	0.00	1.0e+00	MMP9
Lung FVC	1.07	6	2	4.4	-0.21	6.8e-01	AFF1 APOA1 C6orf106 LCAT NRN1L PGAP3
Pulse wave reflection index	1.07	1	0	0.0	0.00	1.0e+00	CTSA
Age at last live birth	1.07	1	1	2.2	0.00	1.0e+00	RNF123
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.07	1	1	2.2	0.00	1.0e+00	PGAP3
Ever smoked	1.07	1	0	0.0	0.00	1.0e+00	PGAP3
Forced expiratory volume in 1-second (FEV1), Best measure	1.06	3	2	4.4	0.00	1.0e+00	ACP2 C6orf106 MYO1F
Comparative body size at age 10	1.06	2	2	4.4	0.00	1.0e+00	B3GNT9 NUP160
Qualifications: None of the above	1.05	2	1	2.2	0.00	1.0e+00	RNF123 TMED5
Hair/balding pattern: Pattern 4	1.05	3	1	2.2	0.00	1.0e+00	C11orf10 DUS2 FEN1
Medication: Paracetamol	1.04	1	0	0.0	0.00	1.0e+00	TMED5
Mean time to correctly identify matches	1.03	1	0	0.0	0.00	1.0e+00	MMP9
Qualifications: O levels/GCSEs or equivalent	1.02	1	0	0.0	0.00	1.0e+00	ZDHHC18
Worry too long after embarrassment	1.01	1	0	0.0	0.00	1.0e+00	KCTD10
Smoking status: Previous	0.98	1	0	0.0	0.00	1.0e+00	MMP9
Forced expiratory volume in 1-second (FEV1)	0.96	3	1	2.2	0.00	1.0e+00	ACP2 C6orf106 MYO1F
Worrier / anxious feelings	0.95	1	0	0.0	0.00	1.0e+00	KCTD10
Past tobacco smoking	0.88	2	0	0.0	0.00	1.0e+00	MMP9 PGAP3
Systolic blood pressure, automated reading	0.71	1	0	0.0	0.00	1.0e+00	RP11-244F12.2
Tanning	0.29	1	0	0.0	0.00	1.0e+00	MLXIPL
Hair Pigment	0.20	9	4	8.9	-0.12	7.5e-01	ACP2 C11orf10 FEN1 HS1BP3 MLXIPL NRN1L PABPC4 RP11-138A9.1 ZDHHC18

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	12	0.62	2.5
The Cancer Genome Atlas	Lung Adenocarcinoma	14	0.50	2.2
GTEx	Cells Transformed fibroblasts	22	0.54	2.0
GTEx	Heart Left Ventricle	11	0.74	2.0
NTR	Blood	21	0.88	2.0
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	21	0.54	2.0
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	9	0.86	2.0
The Cancer Genome Atlas	Prostate Adenocarcinoma	22	0.50	2.0
GTEx	Brain Hypothalamus	3	0.52	1.9
GTEx	Brain Putamen basal ganglia	5	0.82	1.9
GTEx	Prostate	2	0.25	1.9
METSIM	Adipose	27	0.60	1.9
The Cancer Genome Atlas	Colon Adenocarcinoma	11	0.57	1.9
GTEx	Adrenal Gland	6	0.42	1.8
GTEx	Brain Cortex	2	0.20	1.8
GTEx	Brain Hippocampus	3	0.59	1.8
GTEx	Esophagus Mucosa	17	0.53	1.8
GTEx	Heart Atrial Appendage	9	0.58	1.8
GTEx	Skin Sun Exposed Lower leg	17	0.48	1.8
YFS	Blood	26	0.57	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	6	0.58	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	16	0.62	1.8
GTEx	Adipose Subcutaneous	15	0.44	1.7
GTEx	Adipose Visceral Omentum	12	0.61	1.7
GTEx	Artery Coronary	6	0.52	1.7
GTEx	Brain Cerebellar Hemisphere	7	0.48	1.7
GTEx	Brain Cerebellum	6	0.31	1.7
GTEx	Brain Frontal Cortex BA9	3	0.33	1.7
GTEx	Breast Mammary Tissue (Female)	7	0.44	1.7
GTEx	Cells EBV-transformed lymphocytes	4	0.29	1.7
GTEx	Colon Transverse	9	0.45	1.7
GTEx	Liver	3	0.43	1.7
GTEx	Nerve Tibial	25	0.59	1.7
GTEx	Ovary	1	0.11	1.7
GTEx	Pancreas	5	0.31	1.7
GTEx	Skin Not Sun Exposed Suprapubic	12	0.50	1.7
GTEx	Testis	11	0.36	1.7
GTEx	Thyroid	16	0.41	1.7
GTEx	Vagina	2	0.32	1.7
CommonMind	Brain Pre-frontal Cortex	23	0.44	1.7
The Cancer Genome Atlas	Brain Lower Grade Glioma	19	0.47	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	14	0.59	1.7
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	9	0.57	1.7
The Cancer Genome Atlas	Soft Tissue Sarcoma	5	0.50	1.7
The Cancer Genome Atlas	Stomach Adenocarcinoma	11	0.69	1.7
The Cancer Genome Atlas	Testicular Germ Cell Tumors	4	0.33	1.7
The Cancer Genome Atlas	Thyroid Carcinoma	21	0.43	1.7
GTEx	Artery Aorta	9	0.31	1.6
GTEx	Artery Tibial	9	0.25	1.6
GTEx	Brain Caudate basal ganglia	2	0.22	1.6
GTEx	Brain Nucleus accumbens basal ganglia	5	0.59	1.6
GTEx	Breast Mammary Tissue	7	0.37	1.6
GTEx	Esophagus Gastroesophageal Junction	4	0.29	1.6
GTEx	Esophagus Muscularis	10	0.32	1.6
GTEx	Lung	13	0.47	1.6
GTEx	Muscle Skeletal	9	0.32	1.6
GTEx	Pituitary	3	0.27	1.6
GTEx	Small Intestine Terminal Ileum	3	0.66	1.6
GTEx	Spleen	5	0.36	1.6
GTEx	Stomach	2	0.14	1.6
GTEx	Whole Blood	10	0.52	1.6
ROSMAP	Brain Pre-frontal Cortex	12	0.28	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	18	0.43	1.6
The Cancer Genome Atlas	Glioblastoma Multiforme	4	0.41	1.6
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	4	0.27	1.6
GTEx	Colon Sigmoid	2	0.14	1.5
GTEx	Uterus	2	0.36	1.5
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	6	0.39	1.5
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	2	0.16	1.5
The Cancer Genome Atlas	Rectum Adenocarcinoma	4	0.62	1.5
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.21	1.5
GTEx	Breast Mammary Tissue (Male)	2	0.17	1.4
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.15	1.4
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.00	1.4